# US 2008/0306121 A1 · Bisheterocycle Tandem Compounds Useful as Antiviral Agents, the Uses Thereof and the Compositions Comprising Such Compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306121 A1
- Document ID: US20080306121A1
- Status: Published application
- Kind: A1
- Application number: 11/886,593
- Filed: 2006-01-24
- Published: 2008-12-11
- Earliest claimed: 2005-03-18
- Assignees: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- Inventors: Fajun Nan; Jianping Zuo; Wenlong Wang; Haijun Chen; Peilan He
- Web page: https://patentgrep.com/patent/US20080306121A1

## CPC

- C07D 277/56: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- A61P 31/12: Antivirals
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/18: for HIV
- A61P 31/20: for DNA viruses
- A61P 31/22: for herpes viruses
- C07D 277/68: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/14: containing three or more hetero rings
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides small molecule compounds of bisheterocycle in tandem having the structural formula of P1-P2, and the use thereof as well as a composition containing the compounds, each of P1 and P2 is an unsaturated 5-member heterocyclic ring having one or two heteroatoms. This compound may effectively inhibit the replication of influenza virus, the DNA replication of hepatitis B virus (HBV), and the formation of HBsAg and HBeAg. These compounds can be used for the preparation of a medicament for viral diseases, and may overcome the limitations of the known nucleosides drugs, including cytotoxicity, the requirement of other drugs having different structures for against the drug-resistant virus variants induced by long-term therapy. The structure of the compounds according to the invention is relatively simple and easy to be prepared.

## Claims

### Claim 1

A bisheterocycle tandem compound having a structure represented by the following structural formula I:
P1-P2 I
wherein,
Each of P1 and P2 is an unsaturated 5-member heterocyclic ring, and each of the unsaturated 5-member heterocyclic rings P1 and P2 contains one or two heteroatoms selected from the group consisting of N, O or S, and/or each of the unsaturated 5-member heterocyclic rings P1 and P2 is optionally substituted by one or two substitute groups R, and
The said substitute group R is hydrogen; halogen atoms; phenyl or halophenyl; benzyl; C1-C13 alkyl substituted by halogen atom, C1-C6 alkoxyl or hydroxyl; thiazolyl, C2-C6 alkenyl; C3-C6 cycloalkyl; C1-C6 alkyl, C2-C6 alkenyl, phenyl and benzyl substituted by oxygen; C1-C2 alkoxycarbonyl; carboxyl; carbamoyl having the structure formulae
wherein n=1 to 5; acetyl substituted by nitrile group; substituted aminoalkyl having the structure of
wherein,
R9 is hydrogen, isopropyl or benzyl; and
R10 is hydrogen; C2-C8 alkenylacyl; C2-C6 alkanoyl; C1-C6 alkanoyl substituted by alkoxyl; C3-C6 cycloalkanoyl; benzoyl unsubstituted or optionally substituted by one, two or three groups selected from C1-C6 alkoxyl, C1-C6 alkylamino, halogen atom and hydroxyl; benzylacyl; thienyl formacyl; pyridyl formacyl; acylamino; tert-butoxy carbonyl; 2-bromo-thiazolyl-4-formacyl having the structure of
2,5-dibromo-thiazolyl-4-formacyl having the structure of
2-methyl-thiazolyl-4-formacyl having the structure of
pyridyl formacyl substituted by 3-tert-butoxylcarbonylamino having the structure of
2-substituted alkylamino-4-thiazolyl formacyl having the structure of

### Claim 2 (depends on 1)

The compound according to claim 1, wherein, the said compound has the structure represented by the following formula II:
wherein,
R2 is hydrogen, or alkyl substituted by a substituted amino having the structure of
wherein the R9 and R10 have the same definition as in claim 1;
R4 is hydrogen, C1-C6 alkyl or benzyl;
R6 is hydrogen or C1-C6 alkyl; and
R7 is carboxyl, C1-C2 alkoxycarbonyl, carbamoyl having the structure of
or carbamoyl having the structure of
n=1 to 5.

### Claim 3 (depends on 2)

The compound according to claim 2, wherein, the said compound has the structure represented by the following formula III:
wherein,
R7 is carboxyl,
R9 is isopropyl or hydrogen,
R10 is cyclopentyl formacyl, o-methoxyl benzoyl, cyclopentyl-1-ene-acetyl having the structure of
o-fluoro benzoyl, or thienyl formacyl;
or
R7 is methoxylcarbonyl;
R9 is isopropyl, benzyl or hydrogen;
R10 is hydrogen, C2-C8 alkenylacyl; C2-C6 alkanoyl, acetyl substituted by benzyloxy; C3-C6 cycloalkanoyl; benzoyl unsubstituted or optionally substituted by one, two or three groups selected from methoxyl, fluorine atom, amino or hydroxyl; benzylacyl; thienyl formacyl; pyridyl formacyl; pyridylformacyl substituted by 3-tert-butoxylcarbonylamino having the structure of
2-substituted alkylamino-4-thiazolyl formacyl having the structure of
2-bromo-thiazolyl-4-formacyl having the structure of
2,5-dibromo-thiazolyl-4-formacyl having the structure of
or 2-methyl-thiazolyl-4-formacyl having the structure of
or,
R7 is carbamoyl having the structure of
R9 is isopropyl,
R10 is hydrogen, acetyl substituted by benzyloxy, benzoyl unsubstituted or optionally substituted by single fluorine atom, benzylacyl, pyridyl formacyl, pyridyl formacyl substituted by 3-tert-butoxylcarbonylamino having the structure of
2-substituted alkylamino-4-thiazolyl formacyl having the structure of

### Claim 4 (depends on 1)

The compound according to claim 1, wherein, the said compound has the structure represented by the following formula IV:
wherein,
R2, R3, R6 and R7 independently are hydrogen, halogen atoms, phenyl or halophenyl; benzyl; C1-C13 alkyl substituted by halogen atoms, C1-C6 alkoxyl or hydroxyl; C2-C6 alkenyl; C3-C6 cycloalkyl; C1-C6 alkyl, C2-C6 alkenyl, phenyl or benzyl substituted by oxygen atom; amido; C1-C2 alkoxycarbonyl; or carboxyl;
X4 is O, S, NH or N;
X1 is N, NH or CH2;
Y1 is O, S or NH; and
Y4 is N or CH2.

### Claim 5 (depends on 4)

The compound according to claim 4, wherein,
when R2 is H and Y4 is N,
R3 is C1-C6 alkyl;
R6 is C1-C13 alkyl; phenyl or halophenyl; benzyl; substituted alkyl containing halogen atoms, alkoxyl or hydroxyl; C2-C6 alkenyl; C3-C6 cycloalkyl; or halogen atoms;
R7 is hydrogen; phenyl or halophenyl; benzyl; C1-C13 alkyl; C1-C13 alkyl substituted by halogen atoms, C1-C6 alkoxyl or hydroxyl; C2-C6 alkenyl; C3-C6 cycloalkyl; C1-C6 alkyl substituted by oxygen; C1-C2 alkoxycarbonyl; or carboxyl;
X4 is O, S or NH;
X1 is N or CH2; and
Y1 is O, S or NH.

### Claim 6 (depends on 4)

The compound according to claim 4, wherein,
when R3 is H, R2 is H and Y4 is N,
R6 is C1-C13 alkyl, phenyl or halophenyl; benzyl; C1-C6 alkyl substituted by alkoxyl; C2-C6 alkenyl; C3-C6 cycloalkyl; or halogen atoms;
R7 is hydrogen; phenyl or halophenyl; benzyl; C1-C13 alkyl; C1-C6 alkyl substituted by alkoxyl, C2-C6 alkenyl, C3-C6 cycloalkyl, C1-C2 alkoxycarbonyl, carboxyl;
X4 is O, S or NH;
X1 is N or CH2; and
Y1 is O, S or NH.

### Claim 7 (depends on 1)

The compound according to claim 1, wherein, the said compound has the structure represented by the following formula V:
wherein,
R1 is benzyl, C1-C6 alkyl, or C2-C6 alkenyl;
R6 is C1-C2 alkoxyl;
R3 is thiazolyl, thienyl, phenyl), benzyl, C1-C6 alkyl, C2-C6 alkenyl, or C3-C6 cycloalkyl;
X4 is O or S; and
Y1 is O or S.

### Claim 8 (depends on 1)

A medical composition, which contains an effective therapeutic amount of the compound of claim 1 and conventional pharmaceutic adjuvant.

### Claim 9 (depends on 1)

The use of the compound of claim 1 as an antivirus inhibitor.

### Claim 10 (depends on 1)

The use of the compound of claim 1 in preparation of medicament for viral diseases.

### Claim 11 (depends on 1)

The use of the compound of claim 1 in treating viral diseases.

### Claim 12 (depends on 8)

The use of the medical composition of claim 8 in treating viral diseases.

### Claim 13 (depends on 10)

The use according to claim 10, wherein the viral diseases are the diseases caused by influenza virus, hepatitis virus, herpes virus or AIDS virus.
